INTERACTION BETWEEN CULTURED ENDOTHELIAL CELLS AND ABNORMAL ANTITHROMBIN III "TOYAMA"

1987 ◽  
Author(s):  
N Sakuragawa ◽  
S Saitoh ◽  
K Takahashi

Purpose: Abnormal antithrombin III(AT-III)Toyama showed non-affinity to heparin and heparinoid to show loss of immediate antithrombin activity. On the endothelial cells, there are heparinoids including heparan sulfate. We investigated on the interaction between cultured endothelial cells and abnormal AT-III"Toyama" from the viewpoint of antithrombin activity.Materials and methods: (1) Endothelial cell culture:^125I-labelled normal and abnormal AT-III were placed on the washed endothelial cultured cells in 0.2 ml of RPMI-1640 medium for 15 min at 37°C. The medium was suctioned off and the cell layer was washed with Hank's balanced salt solution. The cells were incubated with 1 ml of heparin(3 ug/ml) for 15 min at 4°C. The radioactivity in the supernatant was counted, and represented AT-III which bound to the cells surface. (2) Antithrombin activity: 0.23 ml of thrombin solution^ U/ml) and 0.03 ml of normal or abnormal AT-III plasma were mixed, and incubated on the cultured cell surface for 5 min at room temperature. The residual thrombin activity was assayed by 0.3 ml of the substrate (S-2238) solution(0.8mM)for 5 min. After these procedures,2 ml of 2% citric acid solution was added to stop the reaction, and 0D(405 nm) was recorded.Results: Abnormal AT-III showed reduced binding-activity to cultured cells to one fifth compared with normal AT-III, and the residual thrombin activity in the abnormal was higher compared with that in normal plasma.Conclusion: Abnormal AT-III showed less binding activity to the cultured endothelial cells, and less thrombin neutralizing activity to show thrombogenic tendency.

1981 ◽  
Vol 46 (03) ◽  
pp. 623-625 ◽  
Author(s):  
B Boneu ◽  
F Bouissou ◽  
M Abbal ◽  
P Sie ◽  
C Caranobe ◽  
...  

SummaryIn order to compare the plasmatic progressive antithrombin activity to the concentration of three thrombin inhibitors, antithrombin III (AT III), α2 macroglobulin (α2, M), α1 anti-trypsin (α1 AT) in nephrotic syndrome, a prospective study was carried out on a group of 28 children affected with the disease. A dramatic reduction of the level of AT III and of α1 AT, two inhibitors of molecular weight close to that of albumin, was observed. The decreased level of AT III was counterbalanced by an increase in α2 M. This phenomenon accounts for the increased progressive antithrombin activity observed in all the affected children. It is suggested that the above compensatory mechanism explains the absence of thrombotic accidents in this series and that the benefit of heparin therapy is doubtful in these conditions.


1981 ◽  
Author(s):  
S Kondo ◽  
T Matsuo ◽  
Y Ohoki ◽  
O Matsuo

In the familial AT III deficiency of a Japanese family, the propositus (a-39-yr old female) and her mother had episodes of recurrent thrombosis and their AT III levels as measured immunologically and biologically were below the normal value. In the plasma of her brother, the AT III concentration as measured immunologically was half of the normal value, but his biological antithrombin activity was within the normal range. The progressive antithrombin activity and antifactor Xa activity of plasma samples in this familial AT III deficiency were within the normal range. Measurements of the rate of thrombin neutralization activity revealed that the brother’s plasma was in the normal range, but the plasma of the propositus and of her mother showed rates of thrombin neutralization activity which were somewhat below the normal value. The rate of thrombin neutralization activity per mg protein of AT III was highest in the plasma of the brother, and became slower in the mother, propositus, and pooled normal plasma in that order. In the plasma of this familial AT III deficiency, the rate of Xa neutralization activity was much slower than the normal value. It is postulated that since the antithrombin of the brother of the propositus was found to react as normal in the neutralization of thrombin, he does not have episodes of thrombosis. Such characteristic hyperfunction of antithrombin in the plasma of the brother may be due to some molecular abnormality of AT III within this hereditary deficient family.


1979 ◽  
Author(s):  
Vivian Chan ◽  
T.K. Chan

We have shown by immunofluorescent technique that the distribution of antithrombin III (ATIII) in human tissues was concentrated around the microvasculature of the lungs and kidneys, as well as veins and small arteries of other organs (liver and spleen). It would seem that ATIII is stored and/or synthesized in the endothelial cells similar to Factor VIII-RAG and Plasminogen Activator. Endothelial cells were isolated from human umbilical cord by collagenase and cultured according to Chemethod described by Shearn etal (1977). In freshly isolated endothelial cells, ATIII could be demonstrated by indirect immunof1uorescent technique and radio immunoassay confirmed the presence of 14.8 ng per 106 cells. After 7 days’ culture, the supernatant from 106 cells contained about 15 ng and the cultured cells (106) contained 16.9 ng ATIII. The presence of ATIII in cultured cells was also confirmed by the positive immunofluorescence. Hence the endothelial cells play an active role in preventing thrombosis by the synthesis and liberation of ATIII, the major natural inhibitor of the intrinsic pathway of Coagulation.Reference: Shearn S.A., Peake I.R., Ciddings J.C., Humphrys J. and Bloom A.L. Thrombosis Research, 11, 43, 1977.


1981 ◽  
Author(s):  
Thomas F Busby ◽  
Donald H Atha ◽  
Kenneth C Ingham

Pasteurization of Antithrombin III (AT III) for 10 hours at 60°C is necessary to reduce the risk of transfusion hepatitis. Addition of appropriate stabilizers can largely prevent the loss of antithrombin activity which otherwise occurs during pasteurization. Studies of the mechanism of denaturation and stabilization have been facilitated by the use of 1,8-anilinonaphthalene sulfonate (ANS) which binds weakly to the inhibitor and whose fluorescence undergoes a sigmoidal response to increasing temperature as the protein unfolds. The extent of the increase in ANS fluorescence correlated roughly with the loss of antithrombin activity and with the extent of protein aggregation as determined by high pressure exclusion chromatography. The midpoint, Td, of the thermal denaturation curve increased by 13 and 19°C in the presence of 0.5 M and 1.0 M sodium citrate respectively. Phosphate, sulfate, and EDTA were also strong stabilizers while the chaotropic anions, iodidé and thiocyanate were potent destabilizers. Heparin, at 10 mg/ml, increased Td by 7°, presumbly through a direct binding mechanism. Reducing agents increased ANS fluorescence by an amount similar to that seen with thermally denatured samples, an effect which was inhibited by heparin but not by citrate. Furthermore, incorporation of 14C-iodoacetamide into AT III during thermal titration was coincident with the increase in ANS fluorescence suggesting that disulfide cleavage is the event which triggers the unfolding of the protein. Samples pasteurized for 10 hours at 60°C in the presence of 0.5 M and 1.0 M citrate retained full antithrombin activity but exhibited evidence of minor alterations in the ability to bind heparin.


1979 ◽  
Author(s):  
E. E. Czapek ◽  
H. C. Kwaan

The platelet has been implicated as the nidus around which clot formation occurs. We therefore decided to investigate whether any antithrombotic activity was associated with platelets. Thrombin activity was measured using the chromogenic substrate S-2238. Freshly prepared human platelet rich plasma (PRP) and platelet poor plasma (PPP) were found to have similar amounts of antithrombin activity. This antithrombin activity could be easily removed from a platelet pellet by repeated washing. However, sonicating PRP resulted in the appearance of additional antithrombin activity. After 6 minutes of sonication, the antithrombin activity of PRP decreased to 35% of presonication levels, whereas the antithrombin activity of PPP remained 100%. When subjected to Laurell Immunoelectrophoresis using an antibody to antithrombin III (AT-III), a greater amount of antigen was detected in PRP than in PPP. We conclude that platelets contain antithrombin material which is probably AT-III.


1977 ◽  
Author(s):  
T. Matsuda ◽  
M. Ogawara ◽  
N. Hirabayashi ◽  
T. Seki ◽  
M. Murakami

Among several thrombin inhibitors in normal plasma, antithrombin III (AT-III) and α2-macroglobulin (α2-M) are especially important.However, there has been no appropriate method to determine AT-III and α2-M separately. This study was carried out to differentiate the actions of these two inhibitors of thrombin in plasma. By using single radial immunodiffusion method, we observed that AT-III was adsorbed to bentonite, although α2-M was not. It was necessary to incubate 1 ml of oxalated plasma with 300 mg of bentonite at 37°C for 10 minutes to remove AT-III completely. Supernated plasma contains neither AT-III nor fibrinogen which affects antithrombin activity of plasma. From these results, it is evident that antithrombin activity of plasma adsorbed with bentonite was attributed to that of α2-M. Antithrombin activities of plasma adsorbed with bentonite in 20 healthy subjects were significantly correlated with concentrations of α2-M in plasma, measured immunologically (r=+0.87, p<0.001). It is reasonable to presume that difference between antithrombin activity of defibrinated plasma by heating at 56°C for 2 minutes and that of bentonite treated plasma mainly indicates activity of AT-III. These differences measured in 20 healthy individuals were significantly correlated with plasma AT-TH levels, assayed immunochemically (r=+0.53, p<0.01).


1996 ◽  
Vol 270 (6) ◽  
pp. L921-L930 ◽  
Author(s):  
M. Uchiba ◽  
K. Okajima ◽  
K. Murakami ◽  
H. Okabe ◽  
K. Takatsuki

We evaluated the effects of antithrombin III (AT III) on the pulmonary vascular injury induced by injecting rats with lipopolysaccharide (LPS) to investigate the possible usefulness of AT III as a treatment for acute respiratory distress syndrome. The intravenous administration of AT III prevented the pulmonary accumulation of leukocytes (as evaluated by myeloperoxidase activity) and the increase in pulmonary vascular permeability to 125I-bovine serum albumin induced by LPS. The increase in pulmonary vascular permeability induced by LPS administration was unaffected by various anticoagulants but was inhibited by the leukocytopenia induced by nitrogen mustard or by the administration of a granulocyte elastase inhibitor, ONO-5046. AT III given alone, but not heparin plus AT III or Trp49-modified AT III, which lacks affinity for heparin, significantly increased the plasma concentration of 6-keto-prostaglandin F1alpha, suggesting that the interaction of AT III with heparin-like substances at the endothelial cell surface promotes the release of prostacyclin from endothelial cells in vivo. Trp49-modified AT III failed to prevent the LPS-induced accumulation of leukocytes and vascular injury. The pulmonary accumulation of leukocytes and vascular injury induced by LPS were not prevented by administering AT III to rats that were pretreated with indomethacin. The continuous intravenous infusion of prostacyclin prevented the LPS-induced pulmonary accumulation of leukocytes and vascular injury. Findings suggest that AT III depends on its ability to promote the release of prostacyclin, a potent inhibitor of leukocyte activation, from endothelial cells to prevent pulmonary vascular injury induced by LPS.


1991 ◽  
Vol 62 (6) ◽  
pp. 707-716 ◽  
Author(s):  
Takuya Akai ◽  
Toshiyuki Kaji ◽  
Yumiko Hayakawa ◽  
Tomohiro Hayashi ◽  
Nobuo Sakuragawa

Author(s):  
Margaret E. Hogan

Primary cultures of endothelial cells were grown on cross-linked dextran beads to allow electron microscopic observation of Antithrombin III (ATIII) binding.Busch and Owen demonstrated a heparin-like, stationary ATIII cofactor on the surface of bovine aorta endothelial cells. This stationary cofactor was found to have several functional properties in common with the anticoagulant glycosaminoglycans (GAGS) heparin and heparitin sulfate. The purpose of this study was to characterize this cofactor and try to determine more about its function.


1987 ◽  
Vol 57 (01) ◽  
pp. 011-016 ◽  
Author(s):  
I Yudelman

SummaryIndices of fibrinogen cleavage by thrombin (fibrinopeptide A, FPA); by plasmin (BB1-42 and serum FDP); of the platelet release reaction (betathromboglobulin and platelet factor 4); and antithrombin III (AT III) levels were measured serially in 46 patients with pulmonary emboli in whom either substantial (SR) or impaired (IR) resolution was documented. The mean FPA level in the 25 patients with IR was significantly higher than the level in the 21 patients with SR (p <0.01). The increased thrombin activity in the IR group was not due to AT III deficiency or increased platelet reactivity but the elevated FPA levels in the presence of therapeutic levels of anticoagulation indicated that the dose of heparin was inadequate. The higher BB1-42 and FDP levels in this group reflected the increased plasmin activity that follows increased thrombin activity. In a multivariate discriminant analysis, only the FPA data could be used to predict the degree of resolution.Increased thrombin action impairs resolution presumably by producing greater amounts of accreted fibrin on the impacted embolus.


Sign in / Sign up

Export Citation Format

Share Document